TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cochlear Response Telemetry and Hearing Preservation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Candidate for cochlear implantation (with CI522, CI532, CI622, CI632 or Hybrid-L24 (US only) according to local indications~* 18 years of age or older at the time of enrolment~* Pre-operative audiometric threshold in the implanted ear at 500 Hz of better than or equal to 80 dB HL~* Willingness to participate in and to comply with all requirements of the protocol~Exclusion Criteria:~* Prior cochlear implantation in the ear to be implanted~* Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array~* Abnormal cochlear/nerve anatomy on pre-operative CT or MRI imaging (excluding a mild Mondini malformation or Large Vestibular Aqueduct Syndrome)~* Deafness due to lesions of the acoustic nerve or central auditory pathway~* Diagnosis of auditory neuropathy~* Active middle-ear infection~* Additional handicaps that would prevent participation in evaluations~* Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and investigational device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cochlear implant recipients (Type: OTHER): Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Participants With Diabetic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participants with chronic kidney disease presumed due to diabetes Type 1 or Type 2~* Participants with certain levels of kidney function - serum creatinine (SCr) 1.3 to 3.3 mg/dl (115 to 291 micromol/L) inclusive for women and 1.5 to 3.5 mg/dl (132 to 309 micromol/L) inclusive for men, or an estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m²~* Participants with protein in the urine - 24-hour urine protein/creatinine ratio (PCR) greater than or equal to 800 mg/g (greater than or equal to 91 mg/mmol).~* Participants must be on a stable and acceptable dose of an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin II receptor blocker), or not able to tolerate these medications.~Main Exclusion Criteria:~* Female participants who can become pregnant, are pregnant or breastfeeding~* Participants who have any of the following medical conditions (the site research staff will discuss these criteria and determine a participant's ability to participate)~  * Chronic inflammatory or autoimmune diseases~ * Chronic Kidney Disease from causes other than diabetes~ * An organ transplant~ * Too high a blood pressure~ * Viral Hepatitis B or C liver infection, liver cirrhosis, or significant liver disease~ * Recent gastrointestinal bleeding~ * Acute kidney injury within the 3 months before screening~ * Major surgery within 3 months before screening or plan to have it during the study period~ * HIV infection- the virus that causes AIDS~ * Heart disease that is not considered stable~ * Cancer that is too recent or other condition which poses too high a risk for developing cancer~ * Required to take drugs that change the immune system

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- 2 mg LY2382770 (Type: EXPERIMENTAL): None
- 10 mg LY2382770 (Type: EXPERIMENTAL): None
- 50 mg LY2382770 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans referred for cardiac rehabilitation at the VA Boston Healthcare System.~* Moderate to severe OSA (AHI \>15) on home sleep testing.~Exclusion Criteria:~* Dangerous levels of sleepiness (Epworth Sleepiness Scale score \>16 or a report of falling asleep at the wheel of a car within the past 2 years).~* Physical limitation precluding exercise testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Positive Airway Pressure (CPAP) (Type: EXPERIMENTAL): Continuous positive airway pressure
- Healthy Lifestyle and Sleep Education (HLSE) (Type: SHAM_COMPARATOR): Healthy living and sleep education

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization and fulfilling the following criteria:~1. ≥70% left-anterior descendent (LAD) obstruction suitable for surgical revascularization using the left internal mammary artery (LIMA);~2. patients amenable to a off-pump beating heart revascularization procedure;~3. non-LAD coronary lesions suitable for percutaneous coronary artery intervention (PCI), as adjudicated by one interventional cardiologist and one cardiac surgeon;~4. ≥ 70 years of age~5. Written informed consent for the use of personal data~Exclusion Criteria:~1. patients hemodynamically unstable;~2. acute or recent (\< 1 month) myocardial infarction;~3. severe heart failure (NYHA Class IV);~4. creatinine \> 2.2 mg/dl;~5. allergy to radiographic contrast;~6. contraindication to double antiaggregation therapy (DAT) for at least 12 months;~7. previous cardiac surgery of any type;~8. previous thoracic surgery involving left pleural space;~9. previous coronary stenting: within one month for BMS, within 6 months for DES;~10. disabling stroke within previous 6 months;~11. need for concomitant cardiac surgery during index hospitalization;

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hybrid group (Type: None): Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed solitary plasmacytoma of 1 of the following types:~  * Solitary bone plasmacytoma~ * Extraosseus solitary plasmacytoma~* Bone marrow plasmacytosis \< 10% within the past 4 weeks~* Low serum and/or urine M-protein meeting ≥ 1 of the following criteria:~  * Serum IgG \< 3.5 g/dL~ * Serum IgA \< 2.0 g/dL~ * Urine M-protein (kappa or lambda) \< 1.0 g/24 hours~* No lytic lesions on skeletal survey other than a single lesion associated with solitary plasmacytoma within the past 4 weeks~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Hemoglobin ≥ 10 g/dL\* AND/OR~* No hemoglobin 2 g/dL \< lower limit of normal\* (LLN) NOTE: \*Patients with a history of hemoglobin \< 10 g/dL AND/OR \< 2 g/dL \< LLN that has corrected or improved after epoetin alfa but requires continued treatment with epoetin alfa are not eligible~Hepatic~* Not specified~Renal~* Calcium ≤ 10.5 mg/dL OR~* Calcium normal~* Creatinine ≤ 2 mg/dL~Other~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or breast, or stage I or II cancer that is currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* No prior high-dose steroids except to relieve neurological compromise~Radiotherapy~* Prior localized radiotherapy for myeloma allowed~* Concurrent radiotherapy allowed~Surgery~* Prior surgery for myeloma allowed~Other~* No other prior therapy for myeloma~* Concurrent enrollment in protocol SWOG-S0309 (Myeloma Specimen Repository) allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- MRI and PET (Type: OTHER): Magnetic resonance imaging and positron emission tomography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: L-Glutamine Therapy for Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to participate in the study, a patient must meet all of the following inclusion criteria:~* Patient is at least 18 years of age.~* Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia (documented by hemoglobin electrophoresis).~* Patient has had at least two episodes of painful crises within 12 months of the screening visit.~* If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the next 14 months.~* Patient or the patient's legally authorized representative has given written informed consent.~* If the patient is a female of child-bearing potential, she agrees to practice a recognized form of birth control during the course of the study.~* Patient is able to perform exercise tolerance test~Exclusion Criteria:~If the patient meets any of the following criteria, the patient must not be enrolled:~* Patient has a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit.~* Patient has diabetes mellitus with untreated fasting blood sugar \>115 mg/dL.~* Patient has prothrombin time International Normalized Ratio (INR) \> 2.0.~* Patient has serum albumin \< 3.0 g/dl.~* Patient has received any blood products within three weeks of the screening visit.~* Patient has a history of uncontrolled liver disease or renal insufficiency.~* Patient is pregnant or lactating.~* Patient has been treated with an experimental anti-sickling medication/treatment (except hydroxyurea) within 30 days of the screening visit.~* Patient has been treated with an experimental drug within 30 days of the screening visit.~* There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-glutamine (Type: EXPERIMENTAL): L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily \>66.7 at 15 g 2X daily
- Placebo (Type: PLACEBO_COMPARATOR): Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily \>66.7 at 15 g 2X daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: All-On-4® Treatment Concept

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
The subject is at least 18 years of age (or age of consent) and has passed secession of growth~Obtained informed consent from the subject~Edentulous mandible or maxilla providing sufficient bone whereas a fixed NobelProceraTM Implant bridge on four (4) implants is regarded as an appropriate treatment solution~The subject has an osseous architecture enough to receive four implants and a sufficient amount of bone for placing in healed sites implants with a length of at least 8 mm~The implant site is free from infection and extraction remnants Implants will be placed in healed sites.~Good gingival / periodontal / peri-apical status of opposing teeth/implants~The subject fulfills the prerequisite that a harmonic, stable occlusal relationship can be achieved with opposing natural teeth resp. fixed or removable opposing dentition (tooth or implant based~The subjects as well as the implant site(s) fulfill the criteria for immediate loading.~The subject is in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems The subject is available for the 5-year term of the investigation~Exclusion Criteria:~The subject is not able to give her/his informed consent of participating~Health conditions, which do not permit the surgical (including anesthesia) or restorative procedure~Reason to believe that the treatment might have a negative effect on the subject's overall situation (psychiatric problems), as noted in subject records or in subject history Any disorders in the planned implant area such as previous tumors, chronic bone disease or previous irradiation in the head/neck area~Alcohol or drug abuse as noted in subject records or in subject history Smoking of \>10 cigarettes/day~Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake~Pathologic occlusion, e.g. severe bruxism or other destructive habits~Lack of opposing dentition or unstable occlusion~Ongoing infections, endodontic or periodontal problems in opposing teeth or implants~Subject shows an unacceptable oral hygiene~Subject has allergic or adverse reactions to the restorative material.~Bone augmentation of more than 3mm vertical height performed less than 6 months prior to planned implant placement.~Bis-phosphonate therapy~Implant insertion torque is \<35 Ncm or \>70 Ncm

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mandible (Type: EXPERIMENTAL): Nobel Active Nobel Procera IBO
- maxilla (Type: EXPERIMENTAL): Nobel Active Nobel Procera IBO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multimodal Hypoxia Imaging and Intensity Modulated Radiotherapy for Inoperable Non-small-cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented inoperable, histologically confirmed NSCLC stage III~* Sufficient remaining lung function (FeV1\>1.5 l/s or at least 50 % of the respective individual norm value)~* Karnofsky Performance Score of 70 % or higher.~* Patients \> 18 years of age.~* Adequate haematological function (wbc\>3000 x 10\^3 /ml, thc \>100 ×10\^6 /ml, Hb\>10 g/dl)~* Adequate hepatic and renal function~* Written informed consent~Exclusion Criteria:~* Patient refusal~* Severe concurrent systemic disease~* Claustrophobia~* Cardiac pacemaker~* Other malignancies~* Hypersensitivity to x-ray contrast medium or 18F-FMISO~* Severe renal or hepatic insufficiency~* NSCLC stage I, II or IV~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multimodal hypoxia imaging (Type: OTHER): Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intermittent Oro-Esophageal Tube Feeding in Infants With Cerebral Palsy and Dysphagia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meeting the diagnostic criteria of cerebral palsy formulated by the 13th National Conference on Pediatric Cerebral Palsy Rehabilitation;~* age\<1 year;~* diagnosed as dysphagia confirmed by Dysphagia Disorder Survey or pediatric esophagoscopy;~* with a nasogastric tube inserted at admission;~* enteral nutrition support is required and feasible.~Exclusion Criteria:~* with dysphagia caused by other diseases or factors;~* with progressive neurological disease or degenerative neurological disease;~* with severe heart disease, liver or kidney dysfunction, hematological disorders, or other acute and severe symptoms;~* with abnormalities in the oral cavity, pharynx, esophagus, or other parts of the digestive tract;~* with poor compliance.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- the observation group (Type: EXPERIMENTAL): All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.Within 4 hours of admission, the observation group were required to undergo nasogastric tube removal and initiated Intermittent Oro-Esophageal Tube Feeding for nutrition support.
- The control group (Type: ACTIVE_COMPARATOR): All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy, to promote the development of motor and cognitive function, as well as to improve intellectual development. Besides, swallowing function training was also provided, including direct training, indirect training, and compensatory training.The control group was given nutrition support with persistent nasogastric tube feeding , of which the tube passed through the nasal cavity into the stomach.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Immunohistochemical Study of Human Teeth Pulp Capped With Mineral Trioxide Aggregate (MTA) and Novel Endodontic Cement (NEC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients 16-30 year-old~* patients with no systemic disease~* vital mature teeth with closed apex, no caries either clinically or radiographically, and without any restoration~* patients willing to participate in study~Exclusion Criteria:~* patients not in the range of 16-30 year-old~* patients with systemic disease~* nonvital teeth~* open apex teeth~* teeth with caries or restorations~* patients not willing to participate in study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Mineral Trioxide Aggregate(MTA) (Type: EXPERIMENTAL): MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
- NEC cement (Type: EXPERIMENTAL): NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility